Aditxt Confirms Nasdaq Form 25 Filing — Delisting Becomes Effective Within Days
ADTX has more than doubled off its 52-week low of $0.002 on light trading volume (0.1× avg).
Summary
Nasdaq announced it will file Form 25 to complete the delisting of Aditxt's common stock, effective ten days after filing. The stock is now quoted on the OTC Market.
Key Events · Legal and Risk Events · ADTX
-
Nasdaq Form 25 Filing Announced
Nasdaq publicly announced on September 17, 2026 that it will file a Form 25 with the SEC to complete the delisting of Aditxt's common stock from Nasdaq.
-
Delisting Effective Date
The delisting becomes effective ten days after the Form 25 is filed, which is expected around September 27, 2026.
-
OTC Market Quotation
Aditxt's common stock is currently quoted on the OTC Market, having been suspended from Nasdaq since June 25, 2026.
-
Prior Delisting Notice
The Nasdaq Hearings Panel denied the company's request to continue listing on June 23, 2026, and trading was suspended on June 25, 2026.
Analysis · ADTX · Life Sciences
Nasdaq has formally initiated the final step to delist Aditxt's common stock. The Form 25 filing on September 17, 2026 triggers a ten-day countdown, after which the delisting becomes effective. The stock has been suspended from Nasdaq since June 25, 2026, and is now quoted on the OTC Market. This confirms the company's transition to over-the-counter trading, which typically reduces liquidity and institutional access. The company was already under severe financial distress with negative equity and a Nasdaq delisting notice disclosed in its last 10-Q.
How filings like this one have moved
In the 30 days to Sep 27, 2026, 34.7% of the 991 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADTX was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.00 to $26,604.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.